Recombinant Human FGF-19 Instruction

General description

Fibroblast Growth Factor 19 is an endocrine FGF that regulates bile acid synthesis, glucose metabolism, and energy homeostasis. Unlike canonical FGFs, it signals in a hormone-like manner and does not require heparan sulfate for receptor activation. Recombinant Human FGF-19 Protein (Y11621H) is expressed from E. coli cells. It contains AA Phe 27 - Lys 216 (Accession # O95750), and is widely used in advanced cell culture, metabolic research, and liver biology studies.

Application

· Bile Acid Homeostasis Research — Models FGF-19-mediated feedback inhibition of hepatic bile acid synthesis.

· Glucose Metabolism and Insulin Sensitivity Studies — Investigates metabolic regulation in diabetes and obesity models.

· Liver Regeneration and Protection — Promotes hepatocyte proliferation and protects against cholestatic injury.

· Enterohepatic Signaling Research — Studies gut-liver axis communication and metabolic integration.

· Serum-Free Culture Systems — Suitable for chemically defined and xeno-free cell culture media.

Product Specifications

Stability and Reconstitution

36 months at -20°C to -80°C in lyophilized state;

6 months at -20°C to -80°C under sterile conditions after reconstitution;

7-10 days at 2°C to 8°C under sterile conditions after reconstitution;

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

It is recommended to redissolve in sterile deionized water.

Backgroud

Fibroblast Growth Factor 19, also known as FGF-19 or FGF15 in mice, is a member of the endocrine FGF subfamily that includes FGF-21 and FGF-23. Unlike canonical FGFs that act locally through paracrine mechanisms, endocrine FGFs circulate in the bloodstream and regulate distant target organs. FGF-19 is produced by ileal enterocytes in response to bile acid absorption and travels to the liver where it activates FGFR4 in complex with the co-receptor β-Klotho, inhibiting CYP7A1 expression and bile acid synthesis through a negative feedback loop. This enterohepatic signaling axis is critical for maintaining bile acid pool size and preventing cholestatic liver injury. Beyond bile acid regulation, FGF-19 improves glucose tolerance, enhances insulin sensitivity, and promotes glycogen synthesis through mechanisms distinct from its effects on bile acid metabolism. In liver biology, FGF-19 stimulates hepatocyte proliferation without tumorigenic risk, suggesting therapeutic potential for liver regeneration. EastMabBio's mammalian-expressed FGF-19 ensures proper protein folding and post-translational modifications required for β-Klotho-dependent signaling, supporting metabolic research, liver disease modeling, and enterohepatic axis investigations.

Q&A

Q1:  What is FGF-19 mainly used for?

FGF-19 is primarily used for bile acid homeostasis research, glucose metabolism studies, liver regeneration modeling, and enterohepatic signaling research.

Q2: Is this FGF-19 suitable for serum-free culture systems?

Yes. EastMabBio recombinant FGF-19 is compatible with serum-free, xeno-free, and chemically defined media systems.

Q3: How should recombinant FGF-19 be stored?

Lyophilized protein should be stored at -20°C or below. After reconstitution, aliquot and avoid repeated freeze-thaw cycles.

Q4: What shipping conditions are used?

Products are shipped on dry ice with validated cold-chain packaging to maintain stability during international transportation.

Q5: Do you provide QC documents?

Yes. COA, MSDS, TSE-BSE statements, endotoxin reports, bioactivity data, and additional QC documentation are available upon request.